Too few precompetitive consortia are being formed to mitigate lost opportunities and deliver on other potential mutual gains for public and private stakeholders in drug development.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Open innovation and external sources of innovation. An opportunity to fuel the R&D pipeline and enhance decision making?
Journal of Translational Medicine Open Access 08 May 2018
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
FDA. The beginnings: laboratory and animal studies. Information for Consumers (Drugs) http://www.fda.gov/Drugs/ResourcesForYou/Consumers/ucm143475.htm (2011).
Miller, G. Necessity driving leery pharma “open.” FiercebiotechIThttp://www.fiercebiotechit.com/story/necessity-driving-leery-pharma-open/2011-04-04(2013).
Pollack, A. Drug makers join efforts in research. New York Times (20 September 2012).
Cutcher-Gershenfeld, J. & Lawson, C. Valuing the commons: a fundamental challenge across complex systems. (NSF, Washington, DC, 2010).
Bunin, B.A. & Ekins, S. Drug Discov. Today 16, 643–645 (2011).
Lessl, M., Bryans, J.S., Richards, D. & Asadullah, K. Nat. Rev. Drug Discov. 10, 241–242 (2011).
DiMasi, J.A., Hansen, R.W. & Grabowski, H.G. J. Health Econ. 22, 151–185 (2003).
Toronto International Data Release Workshop Authors. Nature 461, 168–170 (2009).
Hunter, J. & Stephens, S. Nat. Rev. Drug Discov. 9, 87–88 (2010).
Munos, B. Clin. Pharmacol. Ther. 87, 534–536 (2010).
Waitz, I., Townsend, J., Cutcher-Gershenfeld, J., Greitzer, E. & Kerrebrock, J. Aviation and the environment: a national vision statement, goals and recommended actions. http://web.mit.edu/aeroastro/partner/reports/congrept_aviation_envirn.pdf (FAA/NASA, Washington, DC, 2004).
Masum, H. & Harris, R. Open source for neglected diseases: magic bullet or mirage? (Results for Development Institute, Washington, DC, 2011).
Cutcher-Gershenfeld, J., Mittleman, B., Dickherber, A., Mayrand-Chung, S. & Franks, A. Stakeholder alignment in the Biomarkers Consortium. (NSF-VOSS EAGER 0956472, Washington, DC, 2012).
Woelfle, M., Olliaro, P. & Todd, M.H. Nat. Chem. 3, 745–748 (2011).
Cutcher-Gershenfeld, J., Barrett, B. & Lawson, C. Building the internal organization to support lateral alignment: a case study of the Office of Environment and Energy, Federal Aviation Administration http://ssrn.com/abstract=2345248 (MIT, Cambridge, Massachusetts, 2005).
Walton, R. & McKersie, R. A Behavioral Theory of Labor Negotiations. (McGraw Hill, New York, 1965).
DiMasi, J.A., Hansen, R.W. & Grabowski, H.G. The price of innovation: new estimates of drug development costs. J. Health Econ. 22, 151–185 (2003).
Wagner, J.A. et al. Clin. Pharmacol. Ther. 86, 619–625 (2009).
Acknowledgements
We appreciate support for this research provided under NSF-VOSS EAGER 0956472, “Stakeholder Alignment in Socio-Technical Systems.”
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Mittleman, B., Neil, G. & Cutcher-Gershenfeld, J. Precompetitive consortia in biomedicine—how are we doing?. Nat Biotechnol 31, 979–985 (2013). https://doi.org/10.1038/nbt.2731
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt.2731
This article is cited by
-
Powered by Open Innovation: Opportunities and Challenges in the Pharma Sector
Pharmaceutical Medicine (2019)
-
Open innovation and external sources of innovation. An opportunity to fuel the R&D pipeline and enhance decision making?
Journal of Translational Medicine (2018)
-
International ethics harmonization and the global alliance for genomics and health
Genome Medicine (2014)